Neogenomics

Neogenomics Debt

The Debt of Neogenomics (NEO) as of Nov 17, 2026 is 472.28 M USD. In the previous year, Debt was 605.33 M USD — a change of -21.98% (lower).

Debt

472.28 MUSD

YoY

-21.98%

Last updated:

In 2025, Neogenomics's total debt was 472.28 M USD, a -21.98% change from the 605.33 M USD total debt recorded in the previous year.

The Neogenomics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
112.30 M USD
Jan 1, 2019
132.88 M USD
Jan 1, 2020
218.22 M USD
Jan 1, 2021
612.79 M USD
Jan 1, 2022
610.93 M USD
Jan 1, 2023
611.68 M USD
Jan 1, 2024
605.33 M USD
Jan 1, 2025
472.28 M USD
The Neogenomics Debt history
YEARDebtYoY
472.28 MUSD-21.98%
605.33 MUSD-1.04%
611.68 MUSD+0.12%
610.93 MUSD-0.30%
612.79 MUSD+180.81%
218.22 MUSD+64.23%
132.88 MUSD+18.32%
112.30 MUSD+6.52%
105.42 MUSD-17.55%
127.86 MUSD+79.13%
71.38 MUSD+741.63%
8.48 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Debt Details

Understanding Neogenomics's Debt Structure

Neogenomics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Neogenomics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Neogenomics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Neogenomics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Neogenomics stock

Debt of Neogenomics is 472.28 M USD in 2025.

Debt of Neogenomics changed from 605.33 M USD to 472.28 M USD, representing a -21.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Neogenomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neogenomics

All Key Metrics — Neogenomics